SCHEMBL25003025

SCHEMBL25003025

CC(C)(C)OC(=O)N1CCN(c2ccc(Cl)s2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPT P10636 3/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.47
CKS1B P61024 2/20 0.46
SKP1 P63208 2/20 0.46
SKP2 Q13309 2/20 0.46
STS P08842 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAP4K4 O95819 1/20 0.45
GPR119 Q8TDV5 4/20 0.44
NPC1 O15118 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL82779 0.84 MAPT (0.50) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL65161 0.82 LMNA (0.48) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL63640 0.82 ALDH1A1 (0.48) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL21538680 0.81 ALDH1A1 (0.47) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL29188742 0.81 ALDH1A1 (0.61) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL63589 0.80 NR1H2 (0.48) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL24963003 0.80 GPR119 (0.53) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL29943980 0.77 ADORA1 (0.45) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL2274835 0.76 GBA1 (0.55) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL25003065 0.76 POLB (0.48) MEN1KMT2AMAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368115-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHUJING BIOPHARMA CO., LTD (CN) 2024-11-07 US disclosed
EP-4382521-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shujing Biopharma Co., Ltd (CN) 2024-06-12 EP disclosed
CN-117769545-A Tri-fused ring derivative-containing regulator, preparation method and application thereof 上海枢境生物科技有限公司 2024-03-26 CN disclosed
WO-2023011608-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海枢境生物科技有限公司 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368115-A1 REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TPH1, TPH2, GAP43 MEN1 2726/4885KMT2A 4130/4885MAPT 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.